Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo

  title={Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo},
  author={Giovanni Battista Cassano and Cristina Toni and Alberto Petracca and Joseph Deltito and Otto Benkert and George Curtis and Hans Hippius and Wolfgang Maier and David Shera and Gerald L. Klerman},
  journal={European Neuropsychopharmacology},

Tables from this paper

Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.

An exhaustive review of the literature showed that alprazolam is significantly superior to placebo, and is at least equally effective in the relief of symptoms as tricyclic antidepressants (TCAs) such as imipramine.

Sertraline in the treatment of panic disorder

Sertraline was effective and safe in reducing panic attacks and dry mouth and ejaculation failure (primarily ejaculation delay) were associated significantly with sERTraline.

CNS Drug Reviews

Alprazolam is a benzodiazepine derivative that is currently used in the treatment of generalized anxiety, panic attacks with or without agoraphobia, and depression. Alprazolam has a fast onset of

Benzodiazepines in Panic Disorder

It is very important to include this class of drugs in the armamentarium for treating PD because the benzodiazepines are efficacious in PD and the physician can manage the concern about dependence and withdrawal.

Antidepressants versus placebo for panic disorder in adults.

Low-quality evidence was found that revealed a benefit for antidepressants as a group in comparison with placebo in terms of efficacy measured as failure to respond, and treatment acceptability, measured by total number of dropouts for any reason.

Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment

Overall, the meta-analysis showed that SSRIs cause more adverse events than BZs in short-term PD treatment, and clinical guidelines based on incontrovertible evidence are needed.

The role of alprazolam for the treatment of panic disorder in Australia

Alprazolam has shown efficacy for control of PD symptoms, particularly in short-term controlled clinical trials, but is no longer recommended as a first-line pharmacological treatment due to concerns about the risks of developing tolerance, dependence and abuse potential.

Antidepressants and benzodiazepines for panic disorder in adults.

Low-quality evidence suggested no difference between antidepressants and benzodiazepines in terms of response rate and confidence interval, and some evidence suggesting that serotonin reuptake inhibitors (SSRIs) are better tolerated than TCAs (when looking at the number of patients experiencing adverse effects).

Benzodiazepines versus placebo for panic disorder in adults.

Two primary outcomes of efficacy and acceptability showed a possible advantage of benzodiazepines over placebo, and the quality of the evidence as low for both primary outcomes was assessed.

ALPRAZOLAM: profilo farmacoeconomico nei disturbi d’ansia e da attacchi di panico

The clinical pharmacology and the therapeutic profile of alprazolam are reviewed and analysed under the pharmacoeconomic perspectives of the italian patients, General Practitioners, NHS and society.



Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety.

Treatment-related side effects that were worse in patients taking alprazolam than in those taking placebo included sedation, fatigue, ataxia, slurred speech, and amnesia, which tended to subside with dose reduction or continued administration of the drug.

Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone.

The different time courses of therapeutic action of imipramine and alprazolam indicate that these drugs ameliorate panic anxiety via different mechanisms, and support the hypotheses that drugs that are efficacious in the treatment of panic disorders act by altering noradrenergic function and that drugs with primary actions on serotonin function are likely to be less effective treatments.

High-potency benzodiazepines for short-term management of panic disorder: the U.S. experience.

  • G. Tesar
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1990
Alprazolam is comparable to but more rapid than antidepressants in its effects and better tolerated and the morbidity and mortality associated with panic disorder suggest that the benefits of benzodiazepine treatment outweigh its risks.

Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects.

It is recommended that patients with panic disorder be treated for a longer period, at least six months, and that medication be tapered over a more prolonged period, for at least eight weeks, especially where high doses are employed.

Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine.

Alprazolam therapy was effective and well tolerated at a mean daily dose of 5.7 mg and Imipramine hydrochloride (175 mg/d) also produced significant panic relief but was associated with poor patient acceptance.

Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study.

Patients with panic disorder or agoraphobia with panic attacks who had been placed on a regimen of tricyclic antidepressant treatment 1 to 4 years earlier reported at least moderate improvement during treatment; however, side effects were often difficult to tolerate, and 35% discontinued tricycleclic treatment on this account.

Maintenance drug therapy of panic disorder.

A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder.

Fluvoxamine was found to be an effective and well-tolerated treatment for panic using clinician- and patient-rated variables and cognitive therapy was not superior to fluvoxamine on any rating.

Comparison of alprazolam, imipramine, and placebo in the treatment of depression.

In a six-week, double-blind multicenter comparison of alprazolam, imipramine hydrochloride, and placebo in the treatment of 723 patients with depression, the two active drugs were statistically more effective than placebo.